Competitive binding studies using three cell lines with different EGFR expression showed that conjugate 5 specifically binds to colon cancer cells overexpressing EGFR (HT-29), while non-specific binding was also observed in cells with low EGFR expression (LOVO). This evidence concerns the gene EGFR and colonic neoplasm.